These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 37659912)

  • 1. Current approach to Waldenström macroglobulinemia.
    Kapoor P; Rajkumar SV
    Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current approach to Waldenström Macroglobulinemia.
    Ravi G; Kapoor P
    Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.
    Thomas SK
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
    Kaedbey R; Forward N; Sehn LH; Shafey M; Doucette S; Chen CI
    Curr Oncol; 2022 Sep; 29(10):7122-7139. PubMed ID: 36290837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
    Kapoor P; Paludo J; Abeykoon JP
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Waldenström macroglobulinemia in 2020.
    Castillo JJ; Treon SP
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
    Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
    Sekiguchi N
    Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is new in the treatment of Waldenstrom macroglobulinemia?
    Castillo JJ; Treon SP
    Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
    Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
    J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
    Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F
    Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.
    Zanwar S; Abeykoon JP
    Ther Adv Hematol; 2022; 13():20406207221093962. PubMed ID: 35510210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and Emerging Treatments for Waldenström Macroglobulinemia.
    Grimont CN; Castillo Almeida NE; Gertz MA
    Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
    Amaador K; Kersten MJ; Minnema MC; Vos JMI
    Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.